• CorMedix Inc CRMD.OQ reported quarterly adjusted earnings of 22 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of five analysts for the quarter was for earnings of 14 cents per share. Wall Street expected results to range from 5 cents to 21 cents per share.

• Revenue was $31.21 million​; analysts expected $26.53 million.

• CorMedix Inc's reported EPS for the quarter was 22 cents​.

• The company reported quarterly net income of $13.46 million.

• CorMedix Inc shares had risen by 33.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 182.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for CorMedix Inc is $17.50

This summary was machine generated from LSEG data March 25 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)